Articles tagged with Biomarkers
A new study found that two simple blood markers—eGFRdiff and GDF-15 levels—can independently predict kidney disease progression and mortality in people with diabetes. Patients with lower eGFRdiff values faced a higher risk of chronic kidney disease, while those with elevated GDF-15 levels were at increased risk of death.
A groundbreaking study found significant mitochondrial cardiolipin dysregulation in patients with bortezomib-induced peripheral neuropathy. The researchers identified diosmin as a promising candidate for targeting this condition, providing new avenues for therapeutic intervention.
Researchers have identified a novel diagnostic tool that can predict patient outcomes for head and neck squamous cell carcinoma. The LIMA1-alpha protein reliably identifies patients who can be cured with surgery alone, avoiding unnecessary oncological treatments.
Aging and depression are linked to complex brain-body communication, with organs aging at different rates and influencing disease susceptibility. Dr. Hamilton Oh's research reveals how immune cells and metabolic organs amplify or dampen mood symptoms, offering novel therapeutic targets.
Researchers highlight microRNAs as crucial biomarkers for diagnosing and monitoring soft tissue sarcomas, with potential for precision medicine. MicroRNAs could help distinguish between tumor types and guide treatment decisions.
A newly developed AI-based tool uses protein expression to create a stemness index that analyzes tumor similarity to pluripotent stem cells. The model predicts tumor aggressiveness and identifies potential targets for new therapies, offering hope for improved cancer treatment.
The Lundquist Institute has received a $11 million NIH grant to revolutionize the diagnosis and treatment of mucormycosis, a deadly fungal infection. The MUCOR-ADVANCE initiative aims to develop rapid diagnostic tests and immune-based therapies to save lives.
A Finnish population study reveals that middle-aged individuals can have high levels of blood-based biomarkers associated with Alzheimer's disease. The study found a link between kidney disease and higher biomarker levels in middle age, as well as an association between the APOE ε4 gene and older age biomarker concentrations. Further r...
A Phase II study found that 87% of patients with stage III melanoma remained alive and disease-free four years after treatment with nivolumab and relatlimab. Researchers identified unique biomarkers associated with better outcomes, including high TIGIT levels and low B7-H3 levels.
A new review leverages cutting-edge spatial transcriptomics and single-cell omics to identify robust predictive biomarkers for tumor immunotherapy. Representative case studies highlight the potential of spatially resolved markers to guide immunotherapy decisions and predict irAE risk.
The study identified a rare genetic alteration associated with high levels of the ADAM10 protein, which plays a role in breaking down beta-amyloid precursor protein. The researchers aim to develop a panel of prognostic biomarkers to differentiate Alzheimer's disease from other types of dementia.
Researchers at UChicago have developed a more sensitive liquid biopsy test that uses RNA to detect the earliest stages of colorectal cancer with 95% accuracy. The test analyzes RNA modification levels in blood samples, which remain stable regardless of sample preparation.
A new blood biomarker, p-tau217, has been identified as a potential predictor of Alzheimer's disease progression. This marker shows promise in identifying individuals at higher risk of developing the disease, allowing for early intervention and targeted treatment.
Researchers analyzed viral loads during early infection to predict disease progression and developed a method to identify patients at risk of severe symptoms. The study suggests that patients with high viral loads are more likely to experience long-lasting skin lesions and severe symptoms.
Researchers at the University of Illinois developed cryosoret nanoassemblies that enhance fluorescence signals, reducing detection limits for biomarkers. The new platform offers dual-mode interaction between electric and magnetic components of light, promising highly sensitive and tunable biosensing systems.
A Nagoya University group created a sandwich ELISA technique to accurately measure polysialic acid levels in the blood of patients with psychiatric disorders. The technique uses antibodies that minimize non-specific binding, resulting in increased accuracy.
A unique luminescent probe using terbium has been developed to detect β-glucuronidase, an enzyme that can aid in liver cancer diagnosis. The sensor's sensitivity and accuracy are comparable to conventional methods but at a lower cost, making it suitable for resource-limited settings.
Scientists from Pusan National University discovered a genetic biomarker, FCGBP, that is strongly linked to bronchiolitis obliterans syndrome and poor outcomes following lung transplantation. The finding may help identify high-risk patients and devise timely immunosuppressive treatments.
The Association for Molecular Pathology publishes guidelines for detecting homologous recombination deficiency (HRD) in cancer. The report includes recommendations for clinical laboratories, addressing technical aspects of genomic instability and HRD analysis.
A study by researchers at the University of Gothenburg found that newborn babies and patients with Alzheimer's disease share elevated levels of phosphorylated tau, specifically p-tau217. In newborns, this protein reflects a healthy mechanism for brain development, while in Alzheimer's patients, it indicates disease progression.
The study presents ImmunoCheckDB, a web platform that bridges a critical gap in existing resources by enabling pan-cancer exploration of immune checkpoint inhibitor therapies through combined meta-analytical and multiomic approaches. It curates 173 studies involving 93,234 individuals across 18 cancer types and 30 ICI regimens.
A study found that individuals with short leukocyte telomere lengths are more likely to develop age-related brain diseases such as stroke, dementia, and late-life depression. However, those with healthy lifestyle habits may modify the effects of shorter telomeres.
Researchers developed a blood-based proteomic score to predict healthy aging and age-related diseases. A lower score is associated with higher mortality and disease risk, offering a powerful tool for understanding biological aging.
Researchers developed an improved biological ageing clock, LinAge2, that offers doctors a practical way to assess how quickly a person is ageing and what can be done to slow it down. The new algorithm-powered tool outperforms other clinical models in predicting long-term mortality and health outcomes.
A recent study found that MET mutations are associated with enhanced tumor immunogenicity, increased immune cell infiltration, and improved response rates to immune checkpoint blockade. Certain single base substitutions identified as robust predictive biomarkers for survival in pan-cancer immunotherapy.
Researchers found no significant decline in taurine levels with age across humans, monkeys, and mice, suggesting it may not be a reliable marker of aging. Instead, individual physiological contexts shaped by genetic, nutritional, and environmental factors influence its impact.
The new device, nicknamed ABLE, uses a natural process to condense airborne biomarkers into water droplets, allowing for accurate detection at low concentrations. This technology has immediate applications in hospitals and neonatal units, offering a less invasive alternative to blood draws.
The annual Alzheimer's disease drug development pipeline report, led by Dr. Jeffrey Cummings, highlights an increase in active clinical trials and promising drugs, offering reason for optimism. The report assesses 138 drugs currently being studied and notes the growing importance of biomarkers in clinical trials.
Researchers identified C5aR1 as a novel prognostic biomarker and potential therapeutic target for treating metastatic skin cancer. Elevated C5aR1 presence suggests increased metastasis risk and poor survival in patients with cutaneous squamous cell carcinoma.
Researchers discovered biomarkers in gut bacteria and metabolites that can help diagnose and treat gastrointestinal diseases. The study found that certain biomarkers could predict multiple diseases, including gastric cancer and inflammatory bowel disease.
A team of researchers from CRCHUM has identified a set of biomarkers in blood samples that could help diagnose Parkinson's disease. The study found that immune cells in the blood were activated and overexpressed genes associated with stress responses in patients with Parkinson's, forming a unique genetic signature.
A $2.4 million grant will fund the development of an optical imaging technology to image nerve endings in cancer patients with chemotherapy-induced peripheral neuropathy. The goal is to identify potential biomarkers for the disease, enabling early detection and prevention.
Researchers have developed a machine learning tool that identifies metabolism-related molecular profile differences between colorectal cancer patients and healthy individuals. The tool, called PANDA, shows promise as a noninvasive method of diagnosing colorectal cancer and monitoring disease progression.
A new framework for assessing traumatic brain injuries (TBI) will provide more accurate diagnoses and treatments, leading to better patient outcomes. The framework incorporates clinical symptoms, biomarkers, imaging scans, and modifiers to determine the severity of injury and predict recovery.
Researchers identified metabolite patterns in blood and urine related to ultra-processed food intake. A poly-metabolite score was developed, showing potential to objectively measure diet and reduce reliance on self-reported data.
Researchers have developed a 3D micro-printed sensor that uses whispering-gallery-mode microlasers to detect biomarkers with attogram per milliliter sensitivity. The sensors' unique Limacon-shaped design improves efficiency and enables on-chip integration, making them suitable for high-performance lab-on-a-chip devices.
Researchers from USC Keck School of Medicine have developed a low-cost blood test that detects five biomarkers of Alzheimer's disease, including amyloid and tau proteins. The test uses xMAP technology and has the potential to catch the disease in its earliest stages, when treatment might be able to prevent or delay cognitive decline.
Researchers identified changes in stromal tissue associated with increased aggressive breast cancer risk and poorer survival rates among women with benign breast disease. The study used machine learning to detect subtle changes in breast tissue samples from over 9,000 women.
Researchers identify enlarged salience network as first reliable biomarker for depression risk, predicting symptoms before they appear. The network's expansion could enable early identification and intervention, leading to improved quality of life and treatment outcomes.
Researchers identified platelets, C-reactive protein, and chromogranin A as markers that can predict the failure of hormone-sensitive prostate cancer treatment. The study also found that miR-375 expression and lymphocyte-to-monocyte ratio are negative predictors for therapy failure in castration-resistant prostate cancer patients.
Serum Krebs von den Lungen-6 (KL-6) levels are significantly elevated in patients with interstitial lung disease (ILD), suggesting its potential as a diagnostic biomarker. The study also highlights the relationship between KL-6 levels and pulmonary function, specifically forced vital capacity.
Researchers found that patients taking HIV drugs called NRTIs are substantially less likely to develop Alzheimer's disease. The study, led by Jayakrishna Ambati, analyzed data from two large health insurance databases and determined a significant reduction in Alzheimer's risk among patients on NRTIs.
This study reveals periostin as a superior serum biomarker for diagnosing idiopathic pulmonary fibrosis, with high sensitivity and specificity compared to traditional markers. Periostin levels also correlate with disease severity and predict acute exacerbations in IPF patients.
The American Federation for Aging Research (AFAR) presents the Vincent Cristofalo Rising Star Award to Daniel W. Belsky, PhD, for his contributions to aging research and development of biomarkers in aging. He will present a lecture on quantification of biological aging at the 53rd Annual AGE Meeting.
Scientists at Henry Ford Health + Michigan State University Health Sciences have identified a circulating microRNA called miR-126-3p as a mechanistic biomarker of knee osteoarthritis. This discovery may lead to the development of blood tests for early detection and therapeutics for slowing or stopping disease progression.
Researchers from Université Laval discovered a non-invasive retinal exam can detect Parkinson's disease biomarkers, offering early diagnosis and potential intervention. The study found distinct retinal responses to light stimuli in people with Parkinson's compared to healthy individuals.
The National Multiple Sclerosis Society has committed $18.1 million to support research projects aligned with its Pathways to Cures roadmap, which aims to stop MS, restore function, and end the disease. The funding includes 16 research grants and 28 training fellowships in the US and internationally.
Researchers at Karolinska Institutet have identified biomarkers in the blood associated with long COVID symptoms, particularly severe respiratory disorders. The study found that these biomarkers are also linked to inflammatory signal pathways involved in cell death and lung damage.
Research at the University of Bristol has linked mental health conditions like depression and schizophrenia to immune response, suggesting a fundamental change in understanding causal mechanisms. The study identified 29 potential biomarkers that could be used for novel therapeutics in mental health conditions.
A study published in Neurology found that people with higher biological age than their chronological age are more likely to develop dementia. The researchers discovered an association between advanced biological age and changes in brain structures, including loss of gray matter volume.
A study published in Science Translational Medicine found novel biomarkers for tinnitus that correlate with nervous system's 'fight, flight, or freeze' response. Facial movements and pupil dilation measured while listening to unpleasant sounds can predict tinnitus severity.
Researchers at University of Turku discovered a new biomarker that correlates the thickness of inflammatory cell rim surrounding brain lesions with disease severity and speed. The wider the rim, the more aggressively the disease advances, allowing for earlier treatment identification and evaluating drug candidates.
Researchers developed promising α-synuclein PET tracers that can visualize protein aggregates in living patients, enabling earlier diagnosis and treatment monitoring. Tracers like [18F]C05-05 and [18F]ACI-12589 showed significant results in distinguishing synucleinopathies from healthy controls.
A novel approach to analyzing human blood plasma's low-abundant N-glycoproteome has been developed, enabling the reliable identification of rare and modified glycans. This workflow can detect glycoproteins with concentrations as low as 6.31 pg·mL−1, expanding the range by five orders of magnitude.
Researchers at TUM developed an AI-powered algorithm to predict kidney damage in prostate cancer patients undergoing lutetium-177 PSMA therapy. Early detection could enable personalized treatment adjustments to prevent organ damage.
Researchers at Karolinska Institutet have identified new biomarkers in urine that can indicate the presence and severity of prostate cancer with high precision. The findings surpass current blood biomarker PSA in terms of diagnostic accuracy.
New molecular testing methods are transforming post-transplant care by detecting potential heart injury or rejection earlier than traditional biopsies. This enables physicians to reduce immunosuppressive medicine dosage in low-risk patients, potentially improving patient outcomes beyond the first year post-heart transplant.
A misfolded protein in spinal fluid facilitates reliable Parkinson's diagnosis even in its early stages. The biomarker has a sensitivity and specificity of over 90%, making it a promising tool for disease management and potential therapy development.
Researchers identified five blood proteins that can predict liver disease up to 16 years before symptoms. The combined levels of these proteins achieved high accuracy in predicting disease onset and progression, suggesting potential for early diagnosis and treatment.
The study found that serum-derived hsa_circ_101555 showed excellent diagnostic accuracy in differentiating HCC patients from healthy controls. It also demonstrated a prognostic role in predicting tumor progression and response to therapy, with significant correlations with markers of liver inflammation and tumor features.